Let me put it to you in simple terms. Some developmental biotechs pop quite a bit on results for a drug targeted at a very particular disease -- say, irritable bowel syndrome (SGYP). The market is tiny, but the cost of the medicine is high. In this case, PBT2 is targeting a giant market. If you want to stand on the sidelines to a trial result for a drug targeting a huge market, do so. BUT if phase 2 is successful, this drug will catch the attention of a lot of people. I doubt there will be the slow slide down in price you see after a successful phase 2 in other companies. What I will say is that if the phase 2 is successful, and the price pops, you would probably still have the opportunity to make a pretty penny -- just nowhere near as much as those invested now.
Like Briane82, I don't care about convincing you. You should be able to convince yourself by digging into the company, the research, and so on. That is your job. If you don't do it, well, your choice.
Bozo's? Are you trying to write the plural of bozo? And you are commenting on biotech? Well, the illiterate have rights. . .
I am part of a nefarious plot to engage in soft promotion -- not to appear too gung-ho, but just positive. I am paid in stock options as well.
OK, I admit it, PRAN, which runs on a shoestring budget, has been paying me a retainer of $10,000 a month to hang out in a Yahoo message board.
FRom the blurb: "uture Leaders connects leading portfolio managers, bankers and analysts with investor-validated, milestone-rich private and public companies in key therapeutic areas, offering new investment and partnering opportunities and the chance to find companies with tier-jumping potential.
Future Leaders provides the industry's best venue — in a single day — to identify solid investment and partnering prospects. Wall Street and pharma executives will have the opportunity to assess private and public companies with healthy financial profiles, poised to deliver on milestones that could lead to the next tier of valuations.
Last year, more than 500 delegates congregated at Future Leaders, representing top financial institutions, pharmaceutical business development executives, and high net worth investors active in the sector. Last year's Future Leaders audience controlled more than $650 billion in equity assets.
By popular demand the Future Leaders Class of 2014 expands to include a new "Next Wave" track featuring 15 early stage, privately held companies hand-picked by BioCentury. The "Next Wave" track promises to showcase platform plays and product companies advancing their assets to the clinic and proof of clinical concept. Attendees have the opportunity to hear their stories in a 9-minute 'elevator pitch' format and to meet their management teams."
It's happening March 28th in New York. Not sure this was mentioned on the list yet.
I don't get this price rise on no news.
Everyone should read Daniel Kahnemann (yes, that psychologist who is a Nobel Prize winner in economics) on the cognitive mistakes we make and why. Kahnemann (see his Fast and Slow) shows how there is a predictability to the cognitive mistakes we make, such as being impulsive, buying a stock that is rocketing up in price, and so on. When we invest, we need to tame our implusive, emotional side, and force reason to take over. Sounds obvious, in a way, but Kahnemann shows how, in specific ways, we are always making the same mental mistakes again and again. We just need to apply Kahnemann to investing.
We realize, of course, that you want to get your hands on our shares. That's why we pay no attention to you.
Some developmental biotechs spike one (or two days), drop the third, go up the fourth. It really depends on the news. The news that we are expecting is not "fluffy" news, but more substantial news. Me? I'll hold if the news is good, as I expect that if the news is good, there will be a spike, some retrenchment, followed by a long climb.
tdeank, you have provided some superb posts, but this is not one of them. Personally, I like skeptical voices who have some logic and insight to go with the caution. One can take Bill's arguments or reject them. In this case, it strikes me that Prana will sell some after results. It is not a rich company.
For those of us who have held a long time -- though I have only held since late 2011 -- I don't think of this stock as "down so long" :)
In the good old days, Soviet central planning would invent a nice chart with spurious numbers and put it up, reality be damned . . :)
Please, go back to shoveling. You have contributed nothing to this board so far except whining.
Honestly, take your IQ and USE IT!!!! Google PBT2. Read studies. I don't care if you are not a scientist, ANY smart person can wade through a study. Read some more. Read on metal dyshomeostasis. READ -- instead of your incessant whining about having bought at 13 or whatever. Otherwise -- just sell.
You're trying hard, trying hard, aren't you? Belief in the probable efficacy of PBT2 is based on prior published studies, not on chance. Go run away and bother some other board.